This study aimed to examine the relationship between plasma lyso-Gb1 concentration and treatment outcome, evaluated by the overall achievement rate of therapeutic goals (improvements in hepatomegaly, splenomegaly, anemia, thrombocytopenia, bone pain, and bone crisis) in Japanese patients with GD who were treated with velaglucerase alfa. This evidence concerns the gene GABBR1 and anemia.